2189 (2189) Fair Value & Analysis

Healthcare · Market cap HK$460M

2 2189 2189 · HK

PriceHK$0.4600

Fair ValueHK$0.7500

Upside+63.0%

Quality65/100

Watch 2189 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.5300 – HK$0.9400

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$0.4157 – HK$0.4900 · fair‑value band HK$0.5300 – HK$0.9400 · the HK$0.4600 price screens below the HK$0.7500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2189 (2189) currently trades at HK$0.4600, while our model-based Fair Value estimate is HK$0.7500 — implying the stock looks roughly 63.0% undervalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2189 generated revenue of HK$343M at a net margin of 6.8%. Revenue grew 17.8% year over year. It earns a return on equity of 5.2%. Net debt stands at HK$202M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$343M

Revenue growth (YoY) +17.8%

Net margin 6.8%

Return on equity 5.2%

Free cash flow HK$71.1M FY2025

P/E ratio 23.0

More key figures

Operating margin 25.0%

EPS (TTM) HK$0.0300

EPS growth (YoY) +5.1%

Net debt HK$202M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

2189 reported revenue of HK$354M in FY2026 versus HK$320M in FY2022, a compound +2.5%/yr. Reported net income was HK$34.2M in FY2026, compounding −23.3%/yr from FY2022.

Revenue +2.5%/yr

FY22 HK$320M

FY23 HK$408M

FY24 HK$271M

FY25 HK$317M

FY26 HK$354M

Net income −23.3%/yr

FY22 HK$98.9M

FY23 HK$126M

FY24 HK$64.2M

FY25 HK$21.9M

FY26 HK$34.2M

Is 2189 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$96.00	R$25.67	-73%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2189 (2189) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.7500 versus a price of HK$0.4600 — about +63% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2189?

Our model-based fair value for 2189 is HK$0.7500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4600.

What is the quality score of 2189?

2189 has a Quality Score of 65/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2189 (2189)?

2189 reported trailing-twelve-month revenue of about HK$343M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2189?

The net profit margin of 2189 is about 6.8%, meaning it keeps roughly 6.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.